2023-08-02 07:03:13 ET
- Teva Pharmaceutical press release ( NYSE: TEVA ): Q2 Non-GAAP EPS of $0.56 beats by $0.03 .
- Revenue of $3.9B (+2.6% Y/Y) beats by $180M .
- Cash flow generated from operating activities of $324 million.
- Free cash flow of $632 million.
- AUSTEDO ® U.S. revenues of $308 million.
- 2023 revenues outlook revised to $15.0-$15.4 billion from $14.8-$15.4 billion vs. consensus of $15.02B; all other key components reaffirmed: Non-GAAP operating Income of $4.0 – $4.4 billion; Adjusted EBITDA of $4.5 - $4.9 billion; Non-GAAP diluted EPS of $2.25 - $2.55 vs. consensus of $2.29; Free cash flow of $1.7 - $2.1 billion.
For further details see:
Teva Pharmaceutical beats Q2 top and bottom line estimates; raises FY23 revenue outlook